Characterisation of liver fat in the UK Biobank cohort.
Non-alcoholic fatty liver disease and the risk of progression to steatohepatitis, cirrhosis and hepatocellular carcinoma have been identified as major public health concerns. We have demonstrated the feasibility and potential value of measuring liver fat content by magnetic resonance imaging (MRI) i...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0172921&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232529118822400 |
|---|---|
| author | Henry R Wilman Matt Kelly Steve Garratt Paul M Matthews Matteo Milanesi Amy Herlihy Micheal Gyngell Stefan Neubauer Jimmy D Bell Rajarshi Banerjee E Louise Thomas |
| author_facet | Henry R Wilman Matt Kelly Steve Garratt Paul M Matthews Matteo Milanesi Amy Herlihy Micheal Gyngell Stefan Neubauer Jimmy D Bell Rajarshi Banerjee E Louise Thomas |
| author_sort | Henry R Wilman |
| collection | DOAJ |
| description | Non-alcoholic fatty liver disease and the risk of progression to steatohepatitis, cirrhosis and hepatocellular carcinoma have been identified as major public health concerns. We have demonstrated the feasibility and potential value of measuring liver fat content by magnetic resonance imaging (MRI) in a large population in this study of 4,949 participants (aged 45-73 years) in the UK Biobank imaging enhancement. Despite requirements for only a single (≤3min) scan of each subject, liver fat was able to be measured as the MRI proton density fat fraction (PDFF) with an overall success rate of 96.4%. The overall hepatic fat distribution was centred between 1-2%, and was highly skewed towards higher fat content. The mean PDFF was 3.91%, and median 2.11%. Analysis of PDFF in conjunction with other data fields available from the UK Biobank Resource showed associations of increased liver fat with greater age, BMI, weight gain, high blood pressure and Type 2 diabetes. Subjects with BMI less than 25 kg/m2 had a low risk (5%) of high liver fat (PDFF > 5.5%), whereas in the higher BMI population (>30 kg/m2) the prevalence of high liver fat was approximately 1 in 3. These data suggest that population screening to identify people with high PDFF is possible and could be cost effective. MRI based PDFF is an effective method for this. Finally, although cross sectional, this study suggests the utility of the PDFF measurement within UK Biobank, particularly for applications to elucidating risk factors through associations with prospectively acquired data on clinical outcomes of liver diseases, including non-alcoholic fatty liver disease. |
| format | Article |
| id | doaj-art-831dc4b2daaf43f7855d60ad4a82ccee |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-831dc4b2daaf43f7855d60ad4a82ccee2025-08-20T02:03:08ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e017292110.1371/journal.pone.0172921Characterisation of liver fat in the UK Biobank cohort.Henry R WilmanMatt KellySteve GarrattPaul M MatthewsMatteo MilanesiAmy HerlihyMicheal GyngellStefan NeubauerJimmy D BellRajarshi BanerjeeE Louise ThomasNon-alcoholic fatty liver disease and the risk of progression to steatohepatitis, cirrhosis and hepatocellular carcinoma have been identified as major public health concerns. We have demonstrated the feasibility and potential value of measuring liver fat content by magnetic resonance imaging (MRI) in a large population in this study of 4,949 participants (aged 45-73 years) in the UK Biobank imaging enhancement. Despite requirements for only a single (≤3min) scan of each subject, liver fat was able to be measured as the MRI proton density fat fraction (PDFF) with an overall success rate of 96.4%. The overall hepatic fat distribution was centred between 1-2%, and was highly skewed towards higher fat content. The mean PDFF was 3.91%, and median 2.11%. Analysis of PDFF in conjunction with other data fields available from the UK Biobank Resource showed associations of increased liver fat with greater age, BMI, weight gain, high blood pressure and Type 2 diabetes. Subjects with BMI less than 25 kg/m2 had a low risk (5%) of high liver fat (PDFF > 5.5%), whereas in the higher BMI population (>30 kg/m2) the prevalence of high liver fat was approximately 1 in 3. These data suggest that population screening to identify people with high PDFF is possible and could be cost effective. MRI based PDFF is an effective method for this. Finally, although cross sectional, this study suggests the utility of the PDFF measurement within UK Biobank, particularly for applications to elucidating risk factors through associations with prospectively acquired data on clinical outcomes of liver diseases, including non-alcoholic fatty liver disease.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0172921&type=printable |
| spellingShingle | Henry R Wilman Matt Kelly Steve Garratt Paul M Matthews Matteo Milanesi Amy Herlihy Micheal Gyngell Stefan Neubauer Jimmy D Bell Rajarshi Banerjee E Louise Thomas Characterisation of liver fat in the UK Biobank cohort. PLoS ONE |
| title | Characterisation of liver fat in the UK Biobank cohort. |
| title_full | Characterisation of liver fat in the UK Biobank cohort. |
| title_fullStr | Characterisation of liver fat in the UK Biobank cohort. |
| title_full_unstemmed | Characterisation of liver fat in the UK Biobank cohort. |
| title_short | Characterisation of liver fat in the UK Biobank cohort. |
| title_sort | characterisation of liver fat in the uk biobank cohort |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0172921&type=printable |
| work_keys_str_mv | AT henryrwilman characterisationofliverfatintheukbiobankcohort AT mattkelly characterisationofliverfatintheukbiobankcohort AT stevegarratt characterisationofliverfatintheukbiobankcohort AT paulmmatthews characterisationofliverfatintheukbiobankcohort AT matteomilanesi characterisationofliverfatintheukbiobankcohort AT amyherlihy characterisationofliverfatintheukbiobankcohort AT michealgyngell characterisationofliverfatintheukbiobankcohort AT stefanneubauer characterisationofliverfatintheukbiobankcohort AT jimmydbell characterisationofliverfatintheukbiobankcohort AT rajarshibanerjee characterisationofliverfatintheukbiobankcohort AT elouisethomas characterisationofliverfatintheukbiobankcohort |